Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1261-1270 Newer>

The Motley Fool June 23, 2004 Bill Mann	IntraBiotics: The Cat Is Dead Biotechnology company IntraBiotics' stock plunged more than 70% this morning after it stopped clinical trials of its key drug candidate, Iseganan.
The Motley Fool June 23, 2004 Charly Travers	SEC Goes After Drug Fraud On Monday, the Securities and Exchange Commission issued a litigation release announcing a civil lawsuit against Helvetia Pharmaceuticals and four officers of the company.
The Motley Fool June 22, 2004 Charly Travers	Merck Pays Up for a Cancer Drug As demonstrated this morning with the announcement of a major deal with Vertex Pharmaceuticals, Merck is now in the midst of a strategic push to build out its oncology pipeline.
National Defense July 2004	French Army Acquires Transport Chambers A French company is producing a confinement chamber for the movement of biologically contaminated patients. Two of the chambers already are in use by the French Army, and seven more have been ordered.
BusinessWeek June 28, 2004 Amy Barrett	When Medicine And Money Don't Mix Do drugmakers have too much control over lab data?
BusinessWeek June 28, 2004 Kerry Capell	Will This Superdrug Catch A Chill? Negative publicity could jeopardize Crestor, AstraZeneca's cholesterol-buster.
The Motley Fool June 21, 2004 Brian Gorman	Genzyme's Growth Conception Genzyme's biosurgery unit has marketed Seprafilm, indicated to prevent adhesions following abdominal and pelvic operations, since 1996. The company's product could see growth with the increase in C-sections.
The Motley Fool June 21, 2004 Charly Travers	Biotech's Full Monte When it comes to valuing biotech companies, the Monte Carlo simulation lets investors leave the guesswork behind and the random sampling to a computer.
The Motley Fool June 21, 2004 Brian Gorman	Clinical Trials Controversy The American Medical Association wants more transparency in clinical trials, a proposal that may leave drug companies and investors with mixed feelings.
The Motley Fool June 21, 2004 Rich Duprey	aaiPharma Feels the Pain The maker of painkiller Darvocet restates its earnings for the prior two years.
<Older 1261-1270 Newer> Return to current articles.